Anal Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against anal cancer and guarantee the finest results for our customers all over the world.

Anal Cancer

Anal cancer is a type of cancer developed from the anus, which is the distal opening of the gastrointestinal tract. It is a different entity from the more common colorectal cancer. Anal cancer is usually an anal squamous cell carcinoma that arises near the junction of squamous epithelium and is usually associated with human papillomavirus (HPV) infection. It may be keratinized (basaloid) or non-keratinized (cloacogenic). Other types of anal cancer include melanoma, lymphoma, adenocarcinoma or sarcoma. Symptoms of anal cancer include itching or bleeding in the rectum, pain or pressure in the anus or rectum, changes in bowel habits, and lumps in the vicinity of the anus. Bleeding can be serious. Local disease (carcinoma in situ) and prodromal symptoms, anal intraepithelial neoplasia (anal dysplasia or AIN) can be ablated with minimally invasive methods such as infrared photocoagulation. 10-20% of patients with anal cancer will develop distant metastases after treatment. Metastatic or recurrent anal cancer is difficult to treat and usually requires chemotherapy.

Therapeutic Vaccines for Anal Cancer

The incidence of anal cancer is increasing. High risk populations include HIV-positive men who have sex with men (MSM), HIV-negative MSM, HIV-positive women and heterosexual men and women with a history of cervical cancer. Squamous cell cancer of the anus (SCCA) shares biological similarities with cervical cancer, including detectable precancerous lesions and high-risk HPV infection. HPV has been detected in over 90% of anal cancers. HPV 16 is the most common genotype detected, accounting for 70-88% of anal cancers. Given the similarities between cervical and anal HPV-associated diseases, the sentinel study to evaluate the efficacy of the HPV vaccine used AIN2⁺ as a surrogate endpoint for anal cancer. The quadrivalent HPV (qHPV) vaccine has been demonstrated to prevent vaccine associated persistent anal HPV infections as well as anal intraepithelial neoplasia grades 2-3 (AIN2⁺) in young MSM not previously infected.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the anal cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.